“…1,2 Theoretical investigations and in vitro studies demonstrated that pulsed laser systems with short absorption depths, such as the 308-nm xenon chloride laser, permitted controlled atheroablation. 3,4 Excimer laser-guided photoablation eventually received Food and Drug Administration (FDA) clearance as an endovascular debulking technology indicated for use as a treatment option See commentary page 676 for peripheral artery disease (PAD). One limitation of the technology, however, was the inability to create a lumen much larger than the nominal diameter of the ablation catheter.…”